[go: up one dir, main page]

MX2024010924A - Receptor de antigeno quimerico dirigido a tumores. - Google Patents

Receptor de antigeno quimerico dirigido a tumores.

Info

Publication number
MX2024010924A
MX2024010924A MX2024010924A MX2024010924A MX2024010924A MX 2024010924 A MX2024010924 A MX 2024010924A MX 2024010924 A MX2024010924 A MX 2024010924A MX 2024010924 A MX2024010924 A MX 2024010924A MX 2024010924 A MX2024010924 A MX 2024010924A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptor
tumor targeting
car
targeting
Prior art date
Application number
MX2024010924A
Other languages
English (en)
Inventor
Bahram Valamehr
Tom Tong Lee
Martin Hosking
Susumu Yamamoto
Tatsuo Maeda
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of MX2024010924A publication Critical patent/MX2024010924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan receptores de antígeno quimérico (CAR) específicos a un antígeno tumoral seleccionado. También se proporcionan diseños de estructura y perfiles de función de los candidatos CAR proporcionados.
MX2024010924A 2022-04-08 2023-04-07 Receptor de antigeno quimerico dirigido a tumores. MX2024010924A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263329287P 2022-04-08 2022-04-08
PCT/US2023/065537 WO2023196982A1 (en) 2022-04-08 2023-04-07 Chimeric antigen receptor for tumor targeting

Publications (1)

Publication Number Publication Date
MX2024010924A true MX2024010924A (es) 2024-09-11

Family

ID=88243837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010924A MX2024010924A (es) 2022-04-08 2023-04-07 Receptor de antigeno quimerico dirigido a tumores.

Country Status (10)

Country Link
US (2) US20250222029A1 (es)
EP (1) EP4504799A1 (es)
JP (1) JP7707304B2 (es)
KR (1) KR20250004622A (es)
CN (1) CN118871471A (es)
AU (1) AU2023248529A1 (es)
IL (1) IL316102A (es)
MX (1) MX2024010924A (es)
TW (1) TW202440620A (es)
WO (1) WO2023196982A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4253420A4 (en) * 2020-11-30 2024-11-06 ONO Pharmaceutical Co., Ltd. HER2 TARGETING AGENT
WO2023196982A1 (en) 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
CN119256075A (zh) * 2022-04-08 2025-01-03 菲特治疗公司 具有实体瘤靶向骨架的细胞及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
EP3456826B1 (en) 2009-12-10 2023-06-28 Regents of the University of Minnesota Tal effector-mediated dna modification
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
EA201490364A1 (ru) 2011-07-29 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Костимулирующие рецепторы-переключатели
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013266733B2 (en) 2012-05-25 2018-07-05 Cellectis Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
HUE036250T2 (hu) 2013-02-15 2018-06-28 Univ California Kiméra antigénreceptor és eljárások az alkalmazására
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
WO2015123642A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
KR102460549B1 (ko) 2014-03-04 2022-10-28 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
WO2015164594A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3271463A4 (en) 2015-03-18 2018-08-01 Baylor College of Medicine Her2/erbb2 chimeric antigen receptor
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
CN108779174B (zh) 2015-11-04 2022-11-29 希望之城公司 靶向her2的嵌合抗原受体
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN117402829A (zh) 2015-12-14 2024-01-16 贝里坤制药股份有限公司 用于治疗性细胞活化或消除的双重控制
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
KR102786649B1 (ko) 2017-10-11 2025-03-25 페이트 세러퓨틱스, 인코포레이티드 시간적 및 일시적 플라스미드 벡터 발현 시스템을 사용한 세포 재프로그래밍
US11649294B2 (en) * 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
AU2018370195B2 (en) 2017-11-14 2022-01-13 Green Cross Lab Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
MX2020005477A (es) 2017-12-08 2020-11-06 Fate Therapeutics Inc Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
KR20250048610A (ko) 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
SG10201801219VA (en) * 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
US20210024959A1 (en) 2018-03-29 2021-01-28 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
EP3824075A4 (en) 2018-07-17 2022-04-20 The Regents of The University of California T LYMPHOCYTES CHEMERA ANTIGEN RECEPTORS DERIVED FROM PLURIPOTEN STEM CELLS OBTAINED BY GENETIC ENGINEERING
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
CN113853204A (zh) 2019-03-21 2021-12-28 盖米达细胞有限公司 适用于移植组合疗法的扩增nk细胞组分的扩增及其用途
WO2020191434A1 (en) * 2019-03-22 2020-10-01 Olivia Newton-John Cancer Research Institute Anti-her2 binding molecules
WO2021011919A1 (en) 2019-07-17 2021-01-21 Fate Therapeutics, Inc. Immune effector cell engineering and use thereof
BR112022005602A2 (pt) 2019-09-25 2022-07-19 Fate Therapeutics Inc Células efetoras de múltiplos direcionamentos e uso das mesmas
EP4041759A4 (en) 2019-10-07 2023-12-20 Fate Therapeutics, Inc. IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL CULTURE AND USE THEREOF
EP4045539A4 (en) 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
IL293564A (en) 2019-12-06 2022-08-01 Fate Therapeutics Inc Enhancement of ipsc-derived effector immune cell using small compounds
KR20220153578A (ko) 2020-01-23 2022-11-18 엑수마 바이오테크, 코포레이션 Her2에 대한 키메라 항원 수용체 및 이의 사용 방법
CA3184449A1 (en) 2020-05-22 2021-11-25 GC Cell Corporation Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
MX2023004325A (es) 2020-11-04 2023-06-28 Fate Therapeutics Inc Células efectoras inmunitarias y células madre pluripotentes inducidas (ipsc) modificadas para el control heterogéneo de tumores.
IL302471A (en) 2020-11-04 2023-06-01 Fate Therapeutics Inc Engineered ipsc and persistent immune effector cells
CN112391414A (zh) 2020-11-17 2021-02-23 中国医学科学院基础医学研究所 一种靶向her2的car-t表达载体及其构建和应用
EP4253420A4 (en) 2020-11-30 2024-11-06 ONO Pharmaceutical Co., Ltd. HER2 TARGETING AGENT
WO2023196982A1 (en) 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting

Also Published As

Publication number Publication date
CN118871471A (zh) 2024-10-29
JP7707304B2 (ja) 2025-07-14
US20250222029A1 (en) 2025-07-10
US20240002532A1 (en) 2024-01-04
IL316102A (en) 2024-12-01
TW202440620A (zh) 2024-10-16
US12122846B2 (en) 2024-10-22
KR20250004622A (ko) 2025-01-08
EP4504799A1 (en) 2025-02-12
JP2024515919A (ja) 2024-04-11
WO2023196982A1 (en) 2023-10-12
AU2023248529A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
MX2024010924A (es) Receptor de antigeno quimerico dirigido a tumores.
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
BR112022024228A2 (pt) Construtos para receptores de antígeno quiméricos
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
CU20210067A7 (es) Molécula de receptor de antígeno quimérico con dominio de unión al antígeno cldn6
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
NZ604003A (en) Monoclonal antibodies against her2
ZA202206438B (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
WO2021214269A3 (en) Compositions and methods of treating cancer with chimeric antigen receptors
MX2022005821A (es) Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70.
MX2021012336A (es) Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.
AU2021359068A8 (en) Caninized antibodies to canine interleukin-31 receptor alpha
MX2021012160A (es) Anticuerpos antiintegrina y usos de los mismos.
EP4347635A4 (en) CHIMERIC ANTIGEN RECEPTOR TO TARGET HLA-G POSITIVE CANCERS
BR112021020677A2 (pt) Anticorpos contra receptores de antígeno quimérico derivados de 4g7
CL2024002066A1 (es) Receptores de antígeno muc16 quiméricos
ZA202408388B (en) Antibodies targeting sirp-alpha and uses thereof
BR112022003648A2 (pt) Iniciadores e construto de t car complexo de maturação de célula-b
WO2022159653A8 (en) Bispecific chimeric antigen receptors binding to cd19 and cd22
MX2021012820A (es) Receptores de antigenos quimericos resistentes a rituximab y usos de estos.
MX2021009744A (es) Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados.
WO2022094314A8 (en) Dual targeting chimeric antigen receptors
AU2021368741A9 (en) Dual targeting chimeric antigen receptors
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.